Jeffrey Cummings1, Yadi Zhou2, Garam Lee1
1Chambers-Grundy Center for Transformative Neuroscience Department of Brain Health School of Integrated Health Sciences University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
The 2024 Alzheimer's disease drug development pipeline shows a contraction, with fewer trials and drugs compared to 2023. Research continues to focus on disease-modifying agents and symptom management for Alzheimer's disease (AD).
Area of Science: